

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

CD8 antibody [144B]

RRID:AB_443686

Type: Antibody

Proper Citation

Abcam Cat# ab17147, RRID:AB_443686

Antibody Information

URL: http://antibodyregistry.org/AB_443686

Proper Citation: Abcam Cat# ab17147, RRID:AB_443686

Target Antigen: CD8 antibody [144B]

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: IHC-P, IHC-R, WB; Immunohistochemistry - fixed; Western Blot; Immunohistochemistry

Antibody Name: CD8 antibody [144B]

Description: This monoclonal targets CD8 antibody [144B]

Target Organism: human

Antibody ID: AB_443686

Vendor: Abcam

Catalog Number: ab17147

Record Creation Time: 20250820T024445+0000

Record Last Update: 20250820T142414+0000

Ratings and Alerts

No rating or validation information has been found for CD8 antibody [144B].

No alerts have been found for CD8 antibody [144B].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xing Y, et al. (2025) Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer. Developmental cell.

Liu Z, et al. (2025) A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell, 188(11), 3081.

Peng T, et al. (2025) Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. Cell stem cell, 32(4), 652.

Zhang J, et al. (2024) Pyroptotic T cell-derived active IL-16 has a driving function in ovarian endometriosis development. Cell reports. Medicine, 5(3), 101476.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. Cancer immunology research, 12(4), 491.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular cancer therapeutics, 23(1), 68.

Yu J, et al. (2024) Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell, 187(17), 4713.

Zhu R, et al. (2024) ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell metabolism.

Li G, et al. (2023) Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer cell, 41(2), 304.

Trinh T, et al. (2023) CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. iScience, 26(4), 106443.

Wang Y, et al. (2023) Expression of FOXA1 Is Associated with the Tumor-Infiltrating M2 Macrophage, Cytotoxic T Lymphocyte, and Effect of Chemotherapy in Bladder Cancer. Urologia internationalis, 107(1), 58.

Guo D, et al. (2022) Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I?B?. *Cell metabolism*, 34(9), 1312.

Koikawa K, et al. (2021) Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. *Cell*, 184(18), 4753.

Hornburg M, et al. (2021) Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer cell*, 39(7), 928.

Kaddatz H, et al. (2021) Cuprizone-induced demyelination triggers a CD8-pronounced T cell recruitment. *Glia*, 69(4), 925.

Sun Y, et al. (2021) Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. *Cell*, 184(2), 404.

Dong L, et al. (2021) The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. *Cancer cell*, 39(7), 945.

Sun C, et al. (2020) THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. *Cancer cell*, 37(2), 216.